Following successful Phase 3 trials, the US FDA has approved Reltecimod from Israel’s Atox Bio (reported here previously) for the treatment of NSTI (Necrotizing Soft Tissue Infections), commonly referred to as flesh-eating bacteria. (fast-tracked in 2012!)
Treatment for deadly bacteria approved
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.